News

The company has also announced that Gary Tollefson, current CEO and president, is taking a leave of absence from the company. Dr Tollefson is expected to remain a

In this multi-center, randomized, double-blind Phase III clinical trial, 629 adult subjects were enrolled. Subjects with confirmed Clostridium difficile infection (CDI) received either 200mg OPT-80 dosed orally twice

The Familion arrhythmogenic right ventricular cardiomyopathy (ARVC) test is a complex genetic test that sequences the five genes most commonly associated with ARVC (PKP2, DSP, DSG2, DSC2 and

Dr O’Leary will lead the clinical development of ImmunoGen’s product candidates. Prior to joining ImmunoGen, Dr O’Leary was senior medical director of clinical oncology at Bayer where his

Osmetech obtained clearance from the FDA in July 2008 for its eSensor warfarin sensitivity test to be used as an aid in the identification of patients at risk

Based on the company’s success in developing its unique CriticalMix delivery technology and matching pipeline of candidate drugs, the funding was fully supported by existing shareholders. The company

This trial involves the company’s third compound in clinical development to date. This Phase I trial will assess the safety, tolerability and pharmacokinetic profile of Volociximab. Recently, Ophthotech

The ASaP trial is a first-in-man, multi-center, single escalating dose study. The interim results of this trial revealed no drug-related toxicity based on clinical signs, ophthalmic examinations, or

The feasibility study is a prospective, open-label, multi-center trial being performed in Germany. As many as 90 patients will be enrolled and all subjects will undergo clinical follow-up